What Researchers Did
Researchers conducted a randomized, placebo-controlled, double-blind study on 40 patients with advanced chronic multiple sclerosis to evaluate hyperbaric oxygen treatment.
What They Found
Objective improvement was observed in 12 of 17 (71%) patients receiving hyperbaric oxygen compared to 1 of 20 (5%) patients receiving placebo (P < 0.0001). At one-year follow-up, deterioration occurred in 2 patients (12%) in the oxygen group versus 11 patients (55%) in the placebo group (P < 0.0008).
What This Means for Canadian Patients
This study suggests hyperbaric oxygen may offer a transient benefit for advanced multiple sclerosis, but it is not currently recommended for general use. Patients should discuss all treatment options with their healthcare providers, as further research is needed to confirm long-term efficacy and safety.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The study's preliminary nature, relatively small sample size, and need for longer follow-up periods limit the generalizability of its findings.